Analysis of genomic DNA showed that this was the result of a T"6 to C+6 mutation in the donor splice site of intron 7. The proband's parents and 35 normal controls were homozygous for T"6 at this position, indicating that the C+6 mutation was causative.
Of the various types of Ehlers-Danlos syndrome the most severe is type IV (EDS IV).' Patients with this disease can present with a variety of clinical signs. These range from the severe acrogeric type with generalised thin skin, a pinched nose, thin lips, lobeless ears, and premature ageing, to a relatively mild phenotype with variably thin skin, joint laxity, and subtle facial features reminiscent of the more severe phenotype. Fragile blood vessels and hollow organs make EDS IV particularly life threatening, in both the severe and mild forms alike.
Early studies showed that fibroblasts from EDS IV patients secreted lower than normal amounts of type III procollagen.2 Later, the disease was linked to COL3A1, the gene encoding this protein. 3 More recently, with the publication of full length cDNA sequence and partial characterisation of the gene structure, detailed analysis of mutations in EDS IV patients has become possible. Defects have included point mutations,"7 large and small deletions,l_0 and faulty processing of premRNA. "-'4 Most exon skipping mutations have had G+' to A substitutions in donor splice sites, causing severe EDS IV. Exceptions are an IVS25 G+5 to T substitution which caused severe EDS IV,'4 and an IVS20 G+' to A mutation, which resulted in phenotypical overlap between EDS IV and familial aortic aneurysms."
Here we have characterised a new exon skipping mutation of COL3A1. Despite only mild external signs of EDS IV the patient had several dissecting aneurysms. A substitution of IVS7 T"6 led to skipping of exon 7. This is the most 5', completely triple helix encoding exon, of type III collagen, since exon 6 codes partially for the N-peptidase cleavage site and the first nine amino acids of the triple helix.
Materials and methods

THE PATIENT
A 32 year old woman presented with severe right sided abdominal pain suggestive of renal colic. Ultrasound examination showed an infarcted right kidney. Later she developed intermittent claudication of the left leg which improved and eventually disappeared. Angiography showed a right sided renal artery occlusion with an aberrantly supplied lower pole. The left iliac artery was stenosed with a possible dissection. Earlier, while still a student, she developed a transient hemiparesis which was attributed to migraine but with a slightly abnormal arch angiogram. Four years before her renal problems she perforated her bowel shortly after the delivery of her only child by caesarean section. She had varicose veins since teenage which, although surgically treated three times, had relapsed. Her parents, a sister, and son were clinically normal.
On clinical examination she had large eyes, lobeless ears, slightly thin skin over the dorsum of the hands with flattened finger pulps. There was capillary prominence over the shoulders and sacrum, loose jointedness of the knees and wrists, and minor varicose veins. She was classified as having mild vascular nonacrogeric EDS IV. PROTEIN 
ANALYSIS
Fibroblast cell cultures were established, grown, labelled, and the procollagens and collagens analysed as previously described. '5 cDNA SYNTHESIS AND AMPLIFICATION Total cytoplasmic RNA was isolated from cultured skin fibroblasts by lysing with Nonidet P-40 in the presence of vanadyl ribonucleoside complex.'6 First strand cDNA synthesis was performed as described previously6 using one of five antisense primers (see below). Synthesised cDNAs were then amplified as previously described,6 by the polymerase chain reaction,'7 using the appropriate pair of primers. Those products for which sequencing was required were blunt end ligated into M13mpl8 after treatment with polynucleotide kinase to phosphorylate their 5' termini.
OLIGONUCLEOTIDE PRIMERS USED FOR cDNA AMPLIFICATION
The primers CB4103 and CB4105 were used to amplify cDNA encoding peptides CB4, CB2, and CB10. Similarly, the primers CB813 and CB815 were used to amplify cDNA for peptides CB8 and CB1, while primers CB633 and CB635 amplified CB6, CB7, and CB3. The first nine base pairs of each oligonucleotide code for an EcoRI restriction enzyme site. (5) were amplified using RNA from the patient (P) and a normal control (C). The products were then subjected to electrophoresis in an agarose gel. hours in 0 9 mol/l NaCl/0 09 mol/l Na citrate (6 x SSC), 50 mmol/l sodium phosphate pH 6 (fig 1) . These had originally been designed to encode complete cyanogen bromide peptides, for use in combination with peptide mapping of mutations.6710 This time localisation of the mutation was possible without previous peptide mapping (fig 3) . Whereas four of the primer pairs produced amplified products identical to control samples, the amplification product encoding peptides CB6, CB7, and CB3 produced two bands. These were therefore cloned into M13 and sequenced. Several subclones lacked the 54 bp exon 7 (fig 4) suggesting that the mutation caused skipping of this exon during RNA splicing.
Genomic DNA (exons 6 to 8 of COL3A1 1560 bp) from the proband was amplified and cut with RsaI, for which at least one site occurred (within exon 7). The products were cloned into M13 and sequenced to analyse the donor/acceptor splice sites flanking exon 7.
Because of a bias in the type of subclones obtained (only two produced the intron 7 donor splice sequence), a second amplification using primers within exon 7 and exon 8 was performed. This product (-560 bp) was also cloned and sequenced to determine the IVS7 donor splice sequence which was under-represented in subclones of the larger PCR product.
Sequencing showed that the donor/acceptor splice sites of the patient's two alleles differed only at IVS7+6 which was either a T or C Mutations of G + to A in various introns of COL3A1 can produce quite different splicing patterns. Either high levels of exon skipping or insertion of in frame intron sequences are produced by different mutations.'2 Experiments to determine the splicing pattern from the IVS7 C+6 and other exon skipping mutations in COL3A1 are in progress. Most of the shortened form of type III collagen, produced by the proband's fibroblasts, appears to be retained within the cell layer. This is in contrast to a nine amino acid deletion which is efficiently secreted and causes a more severe clinical phenotype.'0 In vivo the N-terminal position of this deletion may also contribute to the mild phenotype as most of the helix Cterminal to this exon will fold normally, from the C-to the N-terminal end. This is in contrast to C-terminal deletions which cause overmodification of the helix N-terminal to the site of mutation. '3 In summary, unlike most exon skipping mutations of COL3A1, this patient does not have the acrogeric form of EDS IV, but more closely resembles the IVS20 G+' to A mutation which presented with phenotypic overlap between EDS IV and aortic aneurysms. Why these two mutations produce a milder phenotype is unclear but it is likely to be complex and involve patterns of missplicing, secretion of abnormal protein from the cell, and position within the collagen helix. We would like to thank Mrs Olive Cutting for technical assistance in tissue culture, and the Medical Illustration Department at the CRC for production of the figures.
